315 related articles for article (PubMed ID: 34575992)
41. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
42. Advances in adult acute lymphoblastic leukemia therapy.
Aldoss I; Stein AS
Leuk Lymphoma; 2018 May; 59(5):1033-1050. PubMed ID: 28745565
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
Barsan V; Ramakrishna S; Davis KL
Curr Oncol Rep; 2020 Jan; 22(2):11. PubMed ID: 31997022
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of relapsed or refractory acute lymphoblastic leukemia].
Imai K
Rinsho Ketsueki; 2017; 58(10):1995-2003. PubMed ID: 28978841
[TBL] [Abstract][Full Text] [Related]
45. A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.
Capria S; Molica M; Mohamed S; Bianchi S; Moleti ML; Trisolini SM; Chiaretti S; Testi AM
Expert Rev Hematol; 2020 Jul; 13(7):755-769. PubMed ID: 32419532
[TBL] [Abstract][Full Text] [Related]
46. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
47. Outcomes after induction failure in childhood acute lymphoblastic leukemia.
Schrappe M; Hunger SP; Pui CH; Saha V; Gaynon PS; Baruchel A; Conter V; Otten J; Ohara A; Versluys AB; Escherich G; Heyman M; Silverman LB; Horibe K; Mann G; Camitta BM; Harbott J; Riehm H; Richards S; Devidas M; Zimmermann M
N Engl J Med; 2012 Apr; 366(15):1371-81. PubMed ID: 22494120
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
49. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
50. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.
Asselin BL; Gaynon P; Whitlock JA
Curr Opin Oncol; 2013 Dec; 25 Suppl 3():S1-13; quiz S14-6. PubMed ID: 24305505
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy in adult acute leukemia.
Blum S; Martins F; Lübbert M
Leuk Res; 2017 Sep; 60():63-73. PubMed ID: 28756350
[TBL] [Abstract][Full Text] [Related]
53. Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
Rose-James A; Shiji R; Kusumakumary P; Nair M; George SK; Sreelekha TT
Med Oncol; 2016 Sep; 33(9):98. PubMed ID: 27449773
[TBL] [Abstract][Full Text] [Related]
54. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
55. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
56. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.
Kaczmarska A; Śliwa P; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203891
[TBL] [Abstract][Full Text] [Related]
57. Acute lymphoblastic leukemia in adults: Steps ahead.
Ribera JM; Vives S
Med Clin (Barc); 2017 Aug; 149(3):119-121. PubMed ID: 28456335
[No Abstract] [Full Text] [Related]
58. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
[TBL] [Abstract][Full Text] [Related]
59. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
60. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy.
Śliwa-Tytko P; Kaczmarska A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
